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Abstract: Randomized controlled trials have conﬁ  rmed the evidence and helped to deﬁ  ne when 
and where non invasive mechanical ventilation (NIV) should be the ﬁ  rst line treatment of acute 
exacerbations of chronic obstructive pulmonary disease (AECOPD). Noninvasive ventilation 
has its best indication in moderate-to-severe respiratory acidosis in patients with AECOPD. For 
this indication, studies conducted in ICU, in wards and in accident and emergency departments 
conﬁ  rmed its effectiveness in preventing endotracheal intubation and reducing mortality. The 
skill of the health care team promotes proper NIV utilization and improves the patient outcome. 
Patients with severe acidosis or with altered levels of consciousness due to hypercapnic acute 
respiratory failure are exposed to high risk of NIV failure. In these patients a NIV trial may 
be attempted in closely monitored clinical settings where prompt endotracheal intubation may 
be assured.
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Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are peri-
ods of acute worsening which greatly affect the health status of those patients with 
an increase in hospital admission and mortality (Donaldson et al 2006). Estimates 
of in-patient mortality range from 4% to 30%, but patients admitted due to acute 
respiratory failure (ARF) experience a higher rate, in particular elderly patients with 
co-morbidities (up to 50%) and those requiring intensive care unit (ICU) admission 
(11%–26%) (American Thoracic Society Statement 1995; Seneff et al 1995; Connors 
et al 1996; Bach et al 2001; Patil et al 2003).
Many causes may potentially be involved in determining ARF during AECOPD, 
such as bronchial infections, bronchospasm, left ventricular failure, pneumonia, pneu-
mothorax and thromboembolism (Derenne et al 1996).
The ARF in the setting of an AECOPD is characterized by the worsening of hypox-
emia and a variable degree of carbon dioxide retention and acidemia.
The capacity of the patient to maintain acceptable indices of gas exchange dur-
ing an AECOPD or the development of ARF depends both from the severity of the 
precipitating cause and from the degree of physiological dysfunction during the stable 
state and the subsequent physiological reserve.
Worsening in ventilation to perfusion ratio (V/Q) mismatching is probably the 
leading mechanism in the occurrence of the hypoxemia by the enlargement of physi-
ological dead space and the rise of wasted ventilation (Calverley 2003).
The increase in airway resistance and the need of a higher minute ventilation may 
result in expiratory ﬂ  ow limitation, dynamic hyperinﬂ  ation and related intrinsic Posi-
tive end expiratory pressure (PEEPi) with subsequent increased inspiratory threshold 
load and dysfunction of the respiratory muscles, which may lead to their fatigue 
(O’Donnell and Parker 2006).
A rapid shallow breathing pattern may ensue in attempting to maintain adequate 
alveolar ventilation when these additional resistive, elastic and inspiratory threshold International Journal of COPD 2007:2(4) 472
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loads are imposed on weakened respiratory muscles, but 
despite increased stimulation of the respiratory centers and 
large negative intrathoracic pressure swings, carbon dioxide 
retention and acidemia may occur.
Dyspnea, right ventricular failure, and encephalopathy 
characterize severe AECOPD complicated by ARF (Rossi 
et al 1995; Similowski et al 1996; Ambrosino et al 1997). 
Arterial pH reﬂ  ects the acute worsening of the alveolar ven-
tilation and, regardless of the chronic level of arterial CO2 
tension (PaCO2), it represents the best marker of the ARF 
severity (Plant and Elliott 2003).
Effectiveness and indications of NIV
The optimum pharmacological treatment of the exacerba-
tions of COPD is based on the so called “ABC approach”, an 
acronym that reﬂ  ects the three classes of drugs (antibiotics, 
bronchodilators, corticosteroids) commonly used.
Controlled oxygen therapy and ventilatory support 
(invasive and non-invasive) are options able to improve 
symptoms and survival of the ARF patients by preventing 
tissue hypoxia and controlling acidosis and hypercapnia 
(Plant and Elliott 2003).
While medical treatment works to maximize lung func-
tion and reverse the precipitating cause of the exacerbations, 
ventilatory support can lower the level of respiratory muscles 
load, thus reducing dyspnea and respiratory rate, and improv-
ing arterial oxygenation, PaCO2, and pH (Rodrìguez-Roisin 
2006; Brochard et al 1990).
Some complications of invasive ventilation are related 
to the intubation or tracheotomy procedure; or to ventilation 
such as ventilator-associated pneumonia (VAP) and other 
nosocomial infections. Non-invasive methods of mechanical 
ventilation (NIV) may avoid most of the complications related 
to the invasive ventilation, ensuring at the same time a similar 
degree of efﬁ  cacy (Pingleton 1994; Girou et al 2000).
Both negative and positive pressure ventilation have been 
used to this purpose (Ambrosino and Corrado 2001); in this 
article we will focus only on non-invasive positive pressure 
ventilation delivered by face or nasal masks.
The international consensus conference on NIV for acute 
respiratory failure stated that “the addition of NIV to standard 
medical treatment of patients with ARF may prevent the 
need for intubation and reduce the rate of complications and 
mortality in patients with hypercapnic respiratory failure” 
(Evans 2001). The reduction of complications related to the 
endotracheal intubation and to the weaning from the invasive 
mechanical ventilation is the main factor affecting mortality 
(Brochard et al 1995; Kramer et al 1995; Keenan et al 2000). 
Moreover, NIV can be applied earlier than intubation in the 
course of ventilatory failure and can be administered outside 
of the ICU (Evans 2001; Mehta and Hill 2001).
Several prospective, randomized, controlled studies 
(Bott et al 1993; Brochard et al 1995; Kramer et al 1995; 
Barbè et al 1996; Celikel et al 1998; Plant et al 2000a; 
Conti et al 2002; Squadrone et al 2004) included in a recent 
meta-analysis (Lightlower et al 2003) and summarized in a 
clinical commentary (Nava et al 2006) conﬁ  rmed the clinical 
efﬁ  cacy of NIV in the treatment of the ARF during AECOPD: 
compared to standard medical therapy alone the application 
of NIV improves survival, reduces the need for endotracheal 
intubation and the rate of complications, and shortens length 
of stay in hospital and in ICU.
In patients with mild to moderate ARF, characterized by 
pH levels between 7.25 and 7.35, NIV was administered for 
few hours per day (12h/day) with low failure rates ranging 
from 15% to 20% (Elliott 2002; Lightowler et al 2003).
In these patients, NIV is indicated to prevent endotracheal 
intubation (Nava et al 2006).
In more severely ill patients (pH  7.25), the rate of NIV 
failure was inversely related to the severity of respiratory 
acidosis, rising up to 52%–62% (Conti et al 2002; Squadrone 
et al 2004). The use of NIV in alternative to the invasive 
ventilation does not affect the mortality rate and the duration 
of ventilatory support, but the patients treated with NIV are 
subjected to a lower rate of complications (VAP, difﬁ  cult 
weaning). In these patients, although exposed to high risk 
of failure, a NIV trial may be justiﬁ  ed, if intubation is not 
strictly required because the need of protecting the airways, 
loss of consciousness or gasping (Conti et al 2002; Squadrone 
et al 2004; Nava et al 2006).
In patients with “mild” exacerbations, not complicated by 
respiratory acidosis, the use of NIV was investigated by few 
studies, including patients in large majority with pH  7.35, 
who failed in demonstrate a better effectiveness of NIV 
than standard medical therapy in preventing the occurrence 
of the ARF. No signiﬁ  cant improvement in mortality and 
hospitalization duration was found, and the tolerance of the 
patients to the NIV was less than 50% (Bardi et al 2000; 
Keenan et al 2005).
NIV as a weaning technique
in AECOPD
In selected invasively ventilated patients with AECOPD who 
had previously failed a weaning trial, NIV may be safely and 
successfully used after a few days of invasive ventilation in 
order to shorten weaning time, reduce ventilator-associated International Journal of COPD 2007:2(4) 473
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complications, and improve survival (Nava et al 1998; Girault 
et al 1999; Ferrer et al 2003). It has been demonstrated NIV is 
as able as invasive ventilation to unload respiratory muscles. 
(Vitacca et al 2001).
Determinants for success or failure
NIV failure occurs more frequently in the ﬁ  rst hours of ven-
tilation, and was reported to be predicted by the following 
clinical factors: severe acidosis, high severity score, severe 
impairment of consciousness, presence of co-morbidities and 
lack of improvement of arterial blood gases after 1–2 hours of 
initial ventilation (Ambrosino et al 1995; Elliott 2002; Nava 
and Ceriana 2004; Confalonieri et al 2005). Nevertheless 
COPD patients with severe ARF treated with NIV, particu-
larly those with more severe functional impairment during 
the stable state, may have a late worsening (after  48hrs), 
often requiring endotracheal intubation, despite an initial 
brief improvement (Moretti et al 2000).
Community acquired pneumonia (CAP) was related to 
a high NIV failure rate in patients with hypoxemic ARF 
(Antonelli et al 2001; Jolliet et al 2001). Concerning the 
efﬁ  ciency of NIV in COPD patients with severe CAP the 
available data are not conclusive. The only one random-
ized study including COPD patients with hypercapnic 
ARF and pneumonia (Confalonieri et al 2001) showed that 
NIV may reduce the rate of intubation and complications 
in comparison with medical therapy. The same advantages 
were not achieved when NIV was compared to conventional 
mechanical ventilation (Honrubia et al 2005). Moreover, 
non-controlled studies reported conﬂ  icting results on the 
outcome of NIV in patients with COPD and pneumonia 
(Meduri et al 1996; Ambrosino et al 1997; Confalonieri 
et al 2005; Phua et al 2005).
When acute exacerbation of COPD with hypercapnic 
ARF is due to cardiogenic edema the treatment with bi-level 
NIV has shown to reduce intubation rate (Masip et al 2000; 
Nava et al 2003).
Contraindications to NIV
Most of the contraindications to NIV as listed in Table 1 
are derived from exclusion criteria for the controlled trials 
(Brochard et al 1995). Therefore it is more correct to state 
that NIV is not proven in these circumstances rather than it 
is contraindicated (Elliott 2004).
Particularly, severe encephalopathy with glasgow coma 
scale (GCS) 10 was considered a contraindication to NIV 
treatment based on the concern that a depressed sensorium 
would predispose the patient to aspiration (Evans 2001). 
More recently some experiences of NIV treatment of patients 
with altered levels of consciousness, due to hypercapnic ARF, 
were reported. These observations need to be conﬁ  rmed by 
randomized controlled trials but suggest the feasibility of 
NIV in such patients, with acceptable rates of failure and 
low rates of aspiration complications (Diaz et al 2005; Scala 
et al 2005).
The use of NIV in different clinical 
settings (where to use NIV?)
Several randomized controlled studies support the effec-
tiveness of NIV in the ICU, in the ward and in the accident 
and emergency departments. Most of these trials included 
patients with an AECOPD and a mild-to-moderate respiratory 
acidosis (Plant and Elliott 2003).
Despite the evidence supporting its use, the NIV avail-
ability and its use varies widely among medical centers and in 
different countries. In 20%–52% of the hospitals in European 
countries NIV was reported unavailable and its utilization 
rate varied from 15% to 80% in COPD patients who need 
ventilatory support (Doherty and Greenstone 1998; Carlucci 
et al 2001; Girault et al 2003). In the United States NIV was 
recently reported to be more available, but frequently (42% 
of the hospitals) resulted underutilized due to inadequate 
equipment and lack of physician knowledge and training 
(Burns et al 2005; Maheshvari et al 2006).
Cost-effectiveness of NIV
By pooling four NIV studies conducted in the ICU the risk of 
intubation was reduced from 63% to 21% and the mortality 
from 25% to 9%; the numbers needed to treat (NNT) were 
2.4 to prevent one intubation and 6.3 to prevent one death; 
in the largest ward trial the probability to meet criteria for 
endotracheal intubation was reduced from 27% to 15%, and 
the real intubation rate from 11% to 6%; the NNT was 8.3 to 
prevent criteria for intubation and 20 to prevent real intuba-
tion (Plant and Elliott 2003).
Non invasive ventilation has been shown to be cost effec-
tive in ICU setting, resulting in an improved clinical outcome 
Table 1 Absolute contraindications for NIV
Cardiac or respiratory arrest
Severe encephalopathy
Severe gastrointestinal bleeding
Severe haemodynamic instability with or without unstable cardiac angina
Facial surgery or trauma
Upper airway obstruction
Inability to protect the airway and/or high risk of aspiration
Inability to clear secretionsInternational Journal of COPD 2007:2(4) 474
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and reduced costs (Keenan 2000); also the use of NIV in ward 
setting reduces mortality, the demand for intensive care, and 
lowers the costs (Plant et al 2003).
Studies speciﬁ  cally addressed to the workload for the 
personnel working with NIV found a different distribution 
of this workload compared to a more traditional approach 
towards patients with ARF (Kramer et al 1995; Nava et al 
1997; Plant et al 2000a). The ﬁ  rst 6 to 8 hours are usually 
associated with a high level of workload, reﬂ  ecting the need 
for the personnel to remain at the bedside (Plant et al 2000a). 
Nevertheless the ﬁ  nancial and human resources implications 
of NIV compared to invasive mechanical ventilation are 
still unclear. There is evidence that some COPD patients 
with less severe ARF without failure of any other organ 
may be successfully treated with lower costs in the respira-
tory intermediate intensive care unit (RIICU) and even in 
the ward than in the ICU (Plant and Elliott 2003; Bertolini 
et al 2005).
Devices (ventilators and interfaces)
In theory NIV could be delivered with similar modalities as 
through an endotracheal tube or a tracheostomy cannula. In 
reality the circumstances of ventilation and the equipment 
available are different (Lellouche et al 2002). NIV is usually 
delivered in assisted ventilation modality but no differences 
in success rate were found when applied in controlled ven-
tilation modality (Vitacca et al 2003).
The presence of gas leaks is a near-constant feature of 
NIV and may affect triggering of the ventilator, delivered 
FiO2, and air humidiﬁ  cation. Differences were found depend-
ing on the ventilator used (“home” vs “ICU” ventilators). 
While home ventilators could adequately compensate large 
gas leaks, ICU ventilators are not able to cope with large leaks 
and needs to titrate trigger sensitivity to avoid auto-trigger-
ing and asynchrony between the patient and the ventilator 
(Nava et al 1997; Richard et al 2002; Tassaux et al 2002; 
Miyoshi et al 2005).
The choice of the interface is one of the crucial issues 
affecting NIV outcome; although face mask is the standard 
interface to deliver NIV in patients with ARF, poor mask 
tolerance, skin lesions, leaks are reported among factors 
causing NIV failure and intubation requirement (Mehta 
2001). No difference in success rate but a better compliance 
with oro-nasal than with nasal mask was reported (Kwok 
et al 2003).
More recently a helmet mask has been introduced to 
deliver NIV reducing discomfort, pressure necrosis of the 
skin, eyes irritation and gastric distension
Some mechanical characteristics of the helmets, pri-
marily its large volume and its highly compliant soft collar 
compared with face mask, might however impair patient-
ventilator interaction. In normal volunteers, when NIV was 
delivered with an helmet an increase in delay time and in 
wasted inspiratory efforts were observed compared to a face 
mask; when a resistive load was imposed, the inspiratory 
effort and patient-ventilator asynchrony increased, and CO2 
clearance worsened (Costa et al 2005; Racca et al 2005; 
Moerer et al 2006).
Regardless to the interface used, in order to reduce the 
risk of nosocomial transmission of respiratory tract infec-
tions and potential risks for the health care workers, careful 
ﬁ  tting on the face and the addition of a viral-bacterial ﬁ  lter 
to the NIV system between the mask and the exhalation port 
should be recommended (Hui et al 2006).
What’s new?
Proportional assist ventilation (PAV), a mode of partial 
ventilatory assistance endowed with characteristics of pro-
portionality and adaptability to the intensity and timing of 
spontaneous ventilatory patterns, when delivered by mask, 
was effective in improving arterial blood gases and reducing 
WOB in severe AECOPD (Vitacca et al 2000), but was not 
clinically superior to mask pressure support in a multicentric 
study (Gay et al 2001; Ambrosino and Rossi 2002).
The use of a helium-oxygen mixture seems very prom-
ising during NIV in AECOPD to further reduce dyspnea 
and WOB and in reducing hospital length of stay, but not 
in improving the success rate (Jaber et al 2000; Jolliet 
et al 2003). The use of heliox is difﬁ  cult because the lack 
of availability of an approved heliox-delivery system, and 
appropriately designed randomized controlled trials are 
needed to deﬁ  ne the role for heliox combined with NIV in 
COPD patients (Hess 2006).
Conclusion
Randomized controlled trials have conﬁ  rmed the evidence 
and helped to deﬁ  ne when and where NIV should be the ﬁ  rst 
line treatment of AECOPD. This does not mean that NIV is a 
panacea for AECOPD. Furthermore great attention must be 
devoted to risk of NIV failure, being always able to intervene 
with appropriate endotracheal intubation.
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